Wang et al. analyze Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment accuracy as screening tests for detecting dementia associated with Alzheimer’s disease (AD). Such tests are at the center of controversy regarding recognition and treatment of AD. The continued widespread use of tools such as MMSE (1975) underscores the failure of advancing cognitive screening and assessment, which has hampered the development and evaluation of AD treatments. It is time to employ readily available, efficient computerized measures for population/mass screening, clinical assessment of dementia progression, and accurate determination of approaches for prevention and treatment of AD and related conditions.
Collaborators GBDDF (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health7, e105–e125.
4.
GilbertKL (2019) Standard, routine cognitive screening: An idea whose time has come?CSA J2, 28–32.
5.
SabbaghMN, BoadaM, BorsonS, ChilukuriM, DoraiswamyPM, DuboisB, IngramJ, IwataA, PorsteinssonAP, PossinKL, RabinoviciGD, VellasB, ChaoS, VergalloA, HampelH (2020) Rationale for early diagnosis of mild cognitive impairment (MCI) supported by emerging digital technologies. J Prev Alzheimers Dis7, 158–164.
6.
SabbaghMN, BoadaM, BorsonS, ChilukuriM, DuboisB, IngramJ, IwataA, PorsteinssonAP, PossinKL, RabinoviciGD, VellasB, ChaoS, VergalloA, HampelH (2020) Early detection of mild cognitive impairment (MCI) in primary care. J Prev Alzheimers Dis7, 165–170.
7.
SabbaghMN, BoadaM, BorsonS, DoraiswamyPM, DuboisB, IngramJ, IwataA, PorsteinssonAP, PossinKL, RabinoviciGD, VellasB, ChaoS, VergalloA, HampelH (2020) Early detection of mild cognitive impairment (MCI) in an at-home setting. J Prev Alzheimers Dis7, 171–178.
8.
AshfordJW (2002) The top ten treatments for preventing Alzheimer’s disease. LIAF-Line: Newsletter of the Long Island Alzheimer’s Foundation; https://www.medafile.com/TOP10-2002-LIAF.pdf
.
9.
BredesenDE (2017) The End of Alzheimer’s: The First Program to Prevent and Reverse Cognitive Decline, Penguin Random House, New York.
10.
HeiszJJ, ClarkIB, BoninK, PaolucciEM, MichalskiB, BeckerS, FahnestockM (2017) The effects of physical exercise and cognitive training on memory and neurotrophic factors. J Cogn Neurosci29, 1895–1907.
SabbaghMN, PerezA, HollandTM, BoustaniM, PeabodySR, YaffeK, BrunoM, PaulsenR, O’BrienK, WahidN, TanziRE (2022) Primary prevention recommendations to reduce the risk of cognitive decline. Alzheimers Dement 10.1002/alz.12535.
13.
WilsonRS, WangT, YuL, GrodsteinF, BennettDA, BoylePA (2021) Cognitive activity and onset age of incident Alzheimer disease dementia. Neurology97, e922–e929.
14.
BellevilleS, CloutierS, MellahS, WillisS, VellasB, AndrieuS, ColeyN, NganduT, MAPT/DSA group (2022) Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia. Alzheimers Dement10.1002/alz.12544.
15.
GuptaS (2022) Keep Sharp: Build a Better Brain at Any Age, Simon & Schuster, New York.
16.
WhitehousePJ (2008) The Myth of Alzheimer’s, St. Martin’s Griffin, New York.
17.
SolomonA, HandelsR, WimoA, AntikainenR, LaatikainenT, LevalahtiE, PeltonenM, SoininenH, StrandbergT, TuomilehtoJ, KivipeltoM, NganduT (2021) Effect of a multidomain lifestyle intervention on estimated dementia risk. J Alzheimers Dis82, 1461–1466.
18.
AlzheimerA (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Z Psychiatrie64, 146–148.
19.
BlessedG, TomlinsonBE, RothM (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry114, 797–811.
20.
NelsonPT, JichaGA, SchmittFA, LiuH, DavisDG, MendiondoMS, AbnerEL, MarkesberyWR (2007) Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: Neuritic plaques and neurofibrillary tangles “do count” when staging disease severity. J Neuropathol Exp Neurol66, 1136–1146.
21.
NelsonPT, AlafuzoffI, BigioEH, BourasC, BraakH, CairnsNJ, CastellaniRJ, CrainBJ, DaviesP, Del TrediciK, DuyckaertsC, FroschMP, HaroutunianV, HofPR, HuletteCM, HymanBT, IwatsuboT, JellingerKA, JichaGA, KovariE, KukullWA, LeverenzJB, LoveS, MackenzieIR, MannDM, MasliahE, McKeeAC, MontineTJ, MorrisJC, SchneiderJA, SonnenJA, ThalDR, TrojanowskiJQ, TroncosoJC, WisniewskiT, WoltjerRL, BeachTG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol71, 362–381.
22.
AshfordJW (2008) Screening for memory disorder, dementia, and Alzheimer’s disease. Aging Health4, 399–432.
23.
ScottJ, MayoAM (2018) Instruments for detection and screening of cognitive impairment for older adults in primary care settings: A review. Geriatr Nurs39, 323–329.
24.
AbeT, KitamuraA, YamashitaM, KimH, ObuchiSP, IshizakiT, FujiwaraY, AwataS, TobaK, IRIDE Cohort Study investigators (2022) Simple screening models for cognitive impairment in community settings: The IRIDE Cohort Study. Geriatr Gerontol Int22, 292–297.
25.
ZhouX, AshfordJW (2019) Advances in screening instruments for Alzheimer’s disease. Aging Med (Milton)2, 88–93.
26.
WildK, HowiesonD, WebbeF, SeelyeA, KayeJ (2008) Status of computerized cognitive testing in aging: A systematic review. Alzheimers Dement4, 428–437.
27.
TsoyE, ZygourisS, PossinKL (2021) Current state of self-administered brief computerized cognitive assessments for detection of cognitive disorders in older adults: A systematic review. J Prev Alzheimers Dis8, 267–276.
28.
ChoiSE, MukherjeeS, GibbonsLE, SandersRE, JonesRN, TommetD, MezJ, TrittschuhEH, SaykinA, LamarM, Rabin L, FoldiNS, SikkesS, JuttenRJ, GrantE, Mac DonaldC, RisacherS, GrootC, OssenkoppeleR, Alzheimer’s Disease Neuroimaging Initiative, CranePK, (2020) Development and validation of language and visuospatial composite scores in ADNI. Alzheimers Dement (N Y)6, e12072.
29.
ArdMC, GalaskoDR, EdlandSD (2013) Improved statistical power of Alzheimer clinical trials by item-response theory: Proof of concept by application to the activities of daily living scale. Alzheimer Dis Assoc Disord27, 187–191.
30.
GorterR, FoxJP, TwiskJW (2015) Why item response theory should be used for longitudinal questionnaire data analysis in medical research. BMC Med Res Methodol15, 55.
31.
AshfordJW, KolmP, ColliverJA, BekianC, HsuLN (1989) Alzheimer patient evaluation and the mini-mental state: Item characteristic curve analysis. J Gerontol44, P139–146.
32.
AshfordJW (2019) The dichotomy of Alzheimer’s disease pathology: Amyloid-beta and tau. J Alzheimers Dis68, 77–83.
33.
MoghavemN, HendersonVW, GreiciusMD (2021) Medicare should not cover aducanumab as a treatment for Alzheimer’s disease. Ann Neurol90, 331–333.
34.
AshfordJW, BorsonS, O’HaraR, DashP, FrankL, RobertP, ShankleWR, TierneyMC, BrodatyH, SchmittFA, KraemerHC, BuschkeH (2007) Should older adults be screened for dementia? It is important to screen for evidence of dementia. Alzheimers Dement3, 75–80.
35.
BayleyPJ, KongJY, MendiondoM, LazzeroniLC, BorsonS, BuschkeH, DeanM, FillitH, FrankL, SchmittFA, PeschinS, FinkelS, AustenM, SteinbergC, AshfordJW (2015) Findings from the National Memory Screening Day program. J Am Geriatr Soc63, 309–314.
36.
AshfordJW, SchmittFA (2001) Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep3, 20–28.
37.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
38.
NasreddineZS, PhillipsNA, BedirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH (2005) The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc53, 695–699.
39.
WangX, LiF, GaoQ, JiangZ, AbudusaimaitiX, YaoJ, ZhuH (2022) Evaluation of the accuracy of cognitive screening tests in detecting dementia associated with Alzheimer’s disease: A hierarchical Bayesian latent class meta-analysis. J Alzheimers Dis87, 285–304.
40.
BorsonS, ScanlanJM, ChenP, GanguliM (2003) The Mini-Cog as a screen for dementia: Validation in a population-based sample. J Am Geriatr Soc51, 1451–1454.
SchmittFA, MendiondoMS, KryscioRJ, AshfordJW (2006) A brief Alzheimer’s screen for clinical practice. Res Pract Alzheimers Dis11, 1–4.
43.
OrenN, Yogev-SeligmannG, AshE, HendlerT, GiladiN, LernerY (2015) The Montreal Cognitive Assessment in cognitively-intact elderly: A case for age-adjusted cutoffs. J Alzheimers Dis43, 19–22.
44.
RossettiHC, LacritzLH, CullumCM, WeinerMF (2011) Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology77, 1272–1275.
45.
CranePK, NarasimhaluK, GibbonsLE, MungasDM, HaneuseS, LarsonEB, KullerL, HallK, van BelleG (2008) Item response theory facilitated cocalibrating cognitive tests and reduced bias in estimated rates of decline. J Clin Epidemiol61, 1018–27.e9.
46.
GalaskoD, AbramsonI, Corey-BloomJ, ThalLJ (1993) Repeated exposure to the Mini-Mental State Examination and the Information-Memory-Concentration Test results in a practice effect in Alzheimer’s disease. Neurology43, 1559–1563.
CummingsJ, AisenP, LemereC, AtriA, SabbaghM, SallowayS (2021) Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res Ther13, 98.
49.
PlancheV, VillainN (2021) US Food and Drug Administration approval of aducanumab-is amyloid load a valid surrogate end point for Alzheimer disease clinical trials?JAMA Neurol78, 1307–1308.
50.
WeinerMW, AisenPS, BeckettLA, GreenRC, JagustW, MorrisJC, OkonkwoO, PerrinRJ, PetersenRC, Rivera MindtM, SaykinAJ, ShawLM, TogaAW, TrojanowskiJQ (2021) Editorial: How will aducanumab approval impact AD research?J Prev Alzheimers Dis8, 391–392.
51.
GlennerGG, WongCW (1984) Alzheimer’s disease and Down’s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun122, 1131–1135.
52.
RumbleB, RetallackR, HilbichC, SimmsG, MulthaupG, MartinsR, HockeyA, MontgomeryP, BeyreutherK, MastersCL (1989) Amyloid A4 protein and its precursor in Down’s syndrome and Alzheimer’s disease. N Engl J Med320, 1446–1452.
53.
AnnusT, WilsonLR, HongYT, Acosta-CabroneroJ, FryerTD, Cardenas-BlancoA, SmithR, BorosI, ColesJP, AigbirhioFI, MenonDK, ZamanSH, NestorPJ, HollandAJ (2016) The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimers Dement12, 538–545.
54.
HeadE, DoranE, NistorM, HillM, SchmittFA, HaierRJ, LottIT (2011) Plasma amyloid-beta as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis23, 399–409.
55.
SalehiA, AshfordJW, MufsonEJ (2016) Editorial: The Link between Alzheimer’s disease and Down syndrome. A historical perspective. Curr Alzheimer Res13, 2–6.
56.
AshfordJW (2004) APOE genotype effects on Alzheimer’s disease onset and epidemiology. J Mol Neurosci23, 157–165.
57.
RaberJ, HuangY, AshfordJW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging25, 641–650.
58.
MorrisJC, RoeCM, XiongC, FaganAM, GoateAM, HoltzmanDM, MintunMA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol67, 122–131.
59.
CummingsJL, GoldmanDP, Simmons-SternNR, PontonE (2022) The costs of developing treatments for Alzheimer’s disease: A retrospective exploration. Alzheimers Dement18, 469–477.
60.
AshfordJW (2002) ApoE4: Is it the absence of good or the presence of bad?J Alzheimers Dis4, 141–143.
61.
AshfordJW, JarvikL (1985) Alzheimer’s disease: Does neuron plasticity predispose to axonal neurofibrillary degeneration?N Engl J Med313, 388–389.
62.
ManlyJJ, GlymourMM (2021) What the Aducanumab approval reveals about Alzheimer disease research. JAMA Neurol78, 1305–1306.
63.
AshfordJW, SoldingerS, SchaefferJ, CochranL, JarvikLF (1981) Physostigmine and its effect on six patients with dementia. Am J Psychiatry138, 829–830.
AshfordJW, SoultanianNS, ZhangSX, GeddesJW (1998) Neuropil threads are collinear with MAP2 immunostaining in neuronal dendrites of Alzheimer brain. J Neuropathol Exp Neurol57, 972–978.
66.
AndrewsJS, DesaiU, KirsonNY, ZichlinML, BallDE, MatthewsBR (2019) Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimers Dement (N Y)5, 354–363.
67.
TrilloL, DasD, HsiehW, MedinaB, MoghadamS, LinB, DangV, SanchezMM, De MiguelZ, AshfordJW, SalehiA (2013) Ascending monoaminergic systems alterations in Alzheimer’s disease. translating basic science into clinical care. Neurosci Biobehav Rev37, 1363–1379.
68.
US Preventive Services Task Force, OwensDK, DavidsonKW, KristAH, BarryMJ, CabanaM, CaugheyAB, DoubeniCA, EplingJWJr., KubikM, LandefeldCS, MangioneCM, PbertL, SilversteinM, SimonMA, TsengCW, WongJB (2020) Screening for cognitive impairment in older adults: US Preventive Services Task Force recommendation statement. JAMA323, 757–763.
69.
AshfordJ, KraemerH, TinklenbergJ, O’HaraR, TaylorJ, YesavageJ (2007) Statistical and pharmacoeconomic issues for Alzheimer’s screening. Alzheimers Dement3, 126.
70.
BorsonS, FrankL, BayleyPJ, BoustaniM, DeanM, LinPJ, McCartenJR, MorrisJC, SalmonDP, SchmittFA, StefanacciRG, MendiondoMS, PeschinS, HallEJ, FillitH, AshfordJW (2013) Improving dementia care: The role of screening and detection of cognitive impairment. Alzheimers Dement9, 151–159.
71.
KeshavanA, PanneeJ, KarikariTK, RodriguezJL, AshtonNJ, NicholasJM, CashDM, CoathW, LaneCA, ParkerTD, LuK, BuchananSM, KeussSE, JamesSN, Murray-SmithH, WongA, BarnesA, DicksonJC, HeslegraveA, PorteliusE, RichardsM, FoxNC, ZetterbergH, BlennowK, SchottJM (2021) Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70. Brain144, 434–449.
72.
ZygourisS, TsolakiM (2015) Computerized cognitive testing for older adults: A review. Am J Alzheimers Dis Other Demen30, 13–28.
73.
InoueM, JinboD, NakamuraY, TaniguchiM, UrakamiK (2009) Development and evaluation of a computerized test battery for Alzheimer’s disease screening in community-based settings. Am J Alzheimers Dis Other Demen24, 129–135.
74.
TarnanasI, TsolakiA, WiederholdM, WiederholdB, TsolakiM (2015) Five-year biomarker progression variability for Alzheimer’s disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?Alzheimers Dement (Amst)1, 521–532.
75.
MeierIB, BueglerM, HarmsR, SeixasA, ColtekinA, TarnanasI (2021) Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer’s disease: The Altoida large cohort study. NPJ Digit Med4, 101.
76.
BottNT, MaderoEN, GlennJM, LangeAR, AndersonJJ, NewtonDO, BrennanAH, BuffaloEA, RentzDM, ZolaSM (2020) Device-embedded cameras for eye tracking-based cognitive assessment: Implications for teleneuropsychology. Telemed J E Health26, 477–481.
77.
DoraiswamyPM, GoldbergTE, QianM, LinaresAR, NwosuA, NinoI, D’AntonioJ, PhillipsJ, NdouliC, HellegersC, MichaelAM, PetrellaJR, AndrewsH, SneedJ, DevanandDP (2022) Validity of the web-based, self-directed, neurocognitive performance test in mild cognitive impairment. J Alzheimers Dis86, 1131–1136.
AshfordJW, Tarpin-BernardF, AshfordCB, AshfordMT (2019) A computerized continuous-recognition task for measurement of episodic memory. J Alzheimers Dis69, 385–399.
80.
van der HoekMD, NieuwenhuizenA, KeijerJ, AshfordJW (2019) The MemTrax Test compared to the Montreal Cognitive Assessment estimation of mild cognitive impairment. J Alzheimers Dis67, 1045–1054.
81.
LiuX, ChenX, ZhouX, ShangY, XuF, ZhangJ, HeJ, ZhaoF, DuB, WangX, ZhangQ, ZhangW, BergeronMF, DingT, AshfordJW, ZhongL (2021) Validity of the MemTrax Memory Test compared to the Montreal Cognitive Assessment in the detection of mild cognitive impairment and dementia due to Alzheimer’s disease in a Chinese cohort. J Alzheimers Dis80, 1257–1267.
82.
RoseAF, GilbertsonAF, CottrellC, TampiRR (2021) Cognitive screening for adult psychiatric outpatients: Comparison of the Cognivue® to the Montreal Cognitive Assessment. World J Psychiatry11, 265–270.
83.
LimoncuH, BozHE, ZygourisS, TsolakiM, GiakoumisD, VotisK, TzovarasD, OzturkV, YenerGG (2021) A virtual reality-based screening test for cognitive impairment in small vessel disease. J Alzheimers Dis Rep5, 161–169.
84.
WeinerMW, NoshenyR, CamachoM, Truran-SacreyD, MackinRS, FlennikenD, UlbrichtA, InselP, FinleyS, FocklerJ, VeitchD (2018) The Brain Health Registry: An internet-based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies. Alzheimers Dement14, 1063–1076.
BergeronMF, LandsetS, Tarpin-BernardF, AshfordCB, KhoshgoftaarTM, AshfordJW (2019) Episodic-memory performance in machine learning modeling for predicting cognitive health status classification. J Alzheimers Dis70, 277–286.
87.
BergeronMF, LandsetS, ZhouX, DingT, KhoshgoftaarTM, ZhaoF, DuB, ChenX, WangX, ZhongL, LiuX, AshfordJW (2020) Utility of MemTrax and machine learning modeling in classification of mild cognitive impairment. J Alzheimers Dis77, 1545–1558.
88.
BenoitM, BerrutG, DoussaintJ, BakchineS, Bonin-GuillaumeS, FremontP, GallardaT, Krolak-SalmonP, MarquetT, MekiesC, SellalF, SchuckS, DavidR, RobertP (2012) Apathy and depression in mild Alzheimer’s disease: A cross-sectional study using diagnostic criteria. J Alzheimers Dis31, 325–334.
89.
MortbyME, LyketsosCG, GedaYE, IsmailZ (2018) Special Issue on mild behavioral impairment and non-cognitive prodromes to dementia. Int Psychogeriatr30, 167–169.
90.
MortbyME, IsmailZ, AnsteyKJ (2018) Prevalence estimates of mild behavioral impairment in a population-based sample of pre-dementia states and cognitively healthy older adults. Int Psychogeriatr30, 221–232.
91.
Castillo-GarciaIM, Lopez-AlvarezJ, OsorioR, OlazaranJ, Ramos GarciaMI, Aguera-OrtizL (2022) Clinical trajectories of neuropsychiatric symptoms in mild-moderate to advanced dementia. J Alzheimers Dis86, 861–875.
92.
Krell-RoeschJ, RakusaM, SyrjanenJA, van HartenAC, LoweVJ, JackCRJr., KremersWK, KnopmanDS, StokinGB, PetersenRC, VassilakiM, GedaYE (2022) Association between CSF biomarkers of Alzheimer’s disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging. Alzheimers Dement, 10.1002/alz.12557.
93.
AquadroE, HyerL, LianB, NegreaC, HambrickMG (2021) The influence of COVID on cognition and behavior in older adults. J Mental Health Aging5, 1–10.
94.
AshfordJW, KumarV, BarringerM, BeckerM, BiceJ, RyanN, VicariS (1992) Assessing Alzheimer severity with a global clinical scale. Int Psychogeriatr4, 55–74.
95.
MarshallGA, ZollerAS, LoriusN, AmariglioRE, LocascioJJ, JohnsonKA, SperlingRA, RentzDM (2015) Functional Activities Questionnaire items that best discriminate and predict progression from clinically normal to mild cognitive impairment. Curr Alzheimer Res12, 493–502.
96.
GalaskoD, BennettD, SanoM, ErnestoC, ThomasR, GrundmanM, FerrisS (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord11(Suppl 2), S33–39.
97.
GalvinJE, RoeCM, PowlishtaKK, CoatsMA, MuichSJ, GrantE, MillerJP, StorandtM, MorrisJC (2005) The AD8: A brief informant interview to detect dementia. Neurology65, 559–564.
BermanSE, KoscikRL, ClarkLR, MuellerKD, BluderL, GalvinJE, JohnsonSC (2017) Use of the Quick Dementia Rating System (QDRS) as an initial screening measure in a longitudinal cohort at risk for Alzheimer’s disease. J Alzheimers Dis Rep1, 9–13.
100.
Tahami MonfaredAA, HoughtonK, ZhangQ, MauskopfJ, Alzheimer’s Disease Neuroimaging Initiative (2022) Staging disease severity using the Alzheimer’s Disease Composite Score (ADCOMS): A retrospective data analysis. Neurol Ther11, 413–434.
101.
CordellCB, BorsonS, BoustaniM, ChodoshJ, ReubenD, VergheseJ, ThiesW, FriedLB (2013) Alzheimer’s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement9, 141–150.
